G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1
Authors:
- 6 March 2015
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 32 (4) , 1-13
Abstract
Estrogen classically drives lung cancer development via estrogen receptor β (ERβ). However, fulvestrant, an anti-estrogen-based endocrine therapeutic treatment, shows limited effects for non-small cell lung cancer (NSCLC) in phase II clinical trials. G protein-coupled estrogen receptor (GPER), a third estrogen receptor that binds to estrogen, has been found to be activated by fulvestrant, stimulating the progression of breast, endometrial, and ovarian cancers. We here demonstrated that cytoplasm-GPER (cGPER) (80.49 %) and nucleus-GPER (53.05 %) were detected by immunohistochemical analysis in NSCLC samples. cGPER expression was related to stages IIIA–IV, lymph node metastasis, and poorly differentiated NSCLC. Selective agonist G1 and 17β-estradiol (E2) promoted the GPER-mediated proliferation, invasion, and migration of NSCLC cells. Additionally, in vitro administration of E2 and G1 increased the number of tumor nodules, tumor grade, and tumor index in a urethane-induced adenocarcinoma model. Importantly, the pro-tumorigenic effects of GPER induced by E2 were significantly reduced by co-administering the GPER inhibitor G15 and the ERβ inhibitor fulvestrant, as compared to administering fulvestrant alone both in vitro and in vivo. Moreover, the phosphorylation of MAPK and Akt was involved in E2/G1-induced GPER activation. In conclusion, our results indicated that a pro-tumor function of GPER exists that mediated E2-/G1-dependent NSCLC progression and showed better efficiency regarding the co-targeting of GPER and ERβ, providing a rationale for further investigation of anti-estrogen clinical therapy.Keywords
This publication has 35 references indexed in Scilit:
- Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancerBMC Cancer, 2012
- Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapyBreast Cancer Research and Treatment, 2012
- The G-protein-coupled estrogen receptor GPER in health and diseaseNature Reviews Endocrinology, 2011
- Lung Cancer and Hormone Replacement Therapy: Association in the Vitamins and Lifestyle StudyJournal of Clinical Oncology, 2010
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trialThe Lancet, 2009
- GPR30 predicts poor survival for ovarian cancerGynecologic Oncology, 2009
- Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosisJournal of Neuroimmunology, 2009
- Estrogen receptor beta (ERβ) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2009
- Stimulating the GPR30 Estrogen Receptor with a Novel Tamoxifen Analogue Activates SF-1 and Promotes Endometrial Cell ProliferationCancer Research, 2009
- Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGFThe EMBO Journal, 2009